Healthcare Industry News: BD
News Release - November 15, 2007
Intranasal Therapeutics, Inc. Names Vice Presidents of Pharmaceutical Development and Commercial DevelopmentMONTVALE, N.J.--(HSMN NewsFeed)--Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced two key additions to the company’s management team. Kathleen Boziwick, previously employed by Pfizer in a variety of commercial development roles for 18 years, has joined ITI as Vice President, Commercial Development. Michael Lusty, Ph.D., who brings extensive experience in the development of both pharmaceuticals and medical devices, joins the company as Vice President, Pharmaceutical Development.
“We are very pleased to welcome both Kathleen Boziwick and Michael Lusty to the ITI management team,” said Peter F. Young, President and Chief Executive Officer of ITI. “Kathleen is a seasoned pharmaceutical executive with a track record of success across a wide range of pharmaceutical activities including product development, strategic planning, and licensing & acquisition. Michael has a strong track record in the conception, development and commercialization of pharmaceuticals and medical devices including extensive knowledge of both US and international regulatory environments. Their combined experience will serve ITI well as we continue to build and advance a portfolio of innovative nasally delivered drugs for the treatment of pain and other central nervous system disorders.”
Prior to joining ITI, Kathleen Boziwick held a series of increasingly responsible management positions at Pfizer, Inc. most recently as Director and Team Leader in the Product Evaluation Group focused on allergy & respiratory, infectious diseases and vaccines, and prior to that as Director, New Product Development in the areas of cardiovascular & metabolic, allergy & respiratory, and dermatology. An 18-year veteran of Pfizer, she began her career within the Consumer Health Care Group. Prior to joining Pfizer, she held positions at Sterling Drug, and Labtest USA. She holds an MBA degree from Pace University.
Michael E. Lusty, Ph.D.
Prior to joining ITI, Michael Lusty was Vice President, Aerosol Research and Development, and a Corporate Officer of Kos Pharmaceuticals, where he was responsible for the development of new products and R&D support of marketed products. Before joining Kos, he was Director of Advanced Product Development for BD Medical, and prior to that was Associate Director, Pharmaceutical Development at the Schering-Plough Research Institute. Dr. Lusty has been an Adjunct Professor within the Temple University School of Pharmacy since 2004. He began his industry career in the Product and Process Engineering Practice of PA Consulting Group, Europe’s premier technology consultancy. Dr. Lusty holds a Ph.D. in physics from the University of St. Andrews, Scotland.
Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative nasally delivered pharmaceutical products, with a particular focus on drugs to treat pain and central nervous system disorders for which there is proven, unsatisfied consumer need. The company currently has several significant products in its clinical development pipeline or in formulation and preclinical development. ITI’s goal is to become a leader in the field of intranasal pharmaceuticals by applying formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. For more information, please visit the ITI web site at www.intranasal.com.
Source: Intranasal Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.